** Shares of PTC Therapeutics PTCT.O fall 1.3% to $45.43 in morning trade
** Company, late on Tuesday, said it has discontinued development of its experimental drug to treat amyotrophic lateral sclerosis (ALS)
** The drug, utreloxastat, failed to slow disease progression, the main goal, in a mid-stage trial - PTCT
** "While this outcome is unfortunate, expectations were low given that drug development in ALS has been difficult and supporting evidence for utreloxastat in ALS was limited" - TD Cowen analysts
** ALS is a rare neurological disease that can break down nerve cells, in the brain and spinal cord, responsible for muscle movements
** Including session moves, stock up about 64% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。